March 2022: Difficulties in Laboratory Diagnosis of Von Willebrand Disease.

Speaker

Sandra Haberichter, Ph.D.
Director of Hemostasis Laboratory & Senior Investigator - Versiti, Blood Research Institute and Diagnostic Labs Associate Adjunct Professor of Pediatrics - Hem/Onc; Medical College of Wisconsin

Difficulties in Laboratory Diagnosis of Von Willebrand Disease.

Although von Willebrand disease (VWD) is the most common inherited bleeding disorder, diagnosis of patients with VWD continues to present challenges. This presentation will offer clinical insights into the new diagnostic methods to identify VWD subtypes. The central role of bleeding assessment tools in quantification of historical bleeding symptoms will be reviewed. The evolution of platelet-dependent assays of von Willebrand factor (VWF) function and the utility of assessing VWF collagen binding will be highlighted.

Learning objectives

  • To understand advances in clinical evaluation of patients with von Willebrand disease.
  • To be able to differentiate the differences between assays of platelet-dependent VWF function
  • To understand the utility of VWF collagen binding activity assays

Watch the Webinar


Answers to Questions from Live Webinar

There are no additional unanswered questions from this webinar.





Answers to Questions from Live Webinar

Below is a list of questions received from the live webinar attendees. Click on any question to reveal the speaker's response.

NEW QUESTION/ANSWER

It is common to see necrosis in cHL, hard to put a number on it offhand.

NEW QUESTION/ANSWER

Classic in the 2017 WHO

NEW QUESTION/ANSWER

It can be expressed in both CHL and ALCL so it may not be reliable.

NEW QUESTION/ANSWER

CD15, CD30, CD20, PAX5, OCT2, BOB1 and CD45 can be helpful.

NEW QUESTION/ANSWER

I have never seen this.

NEW QUESTION/ANSWER

No, there is no clinical role for this at present.

NEW QUESTION/ANSWER

This would be highly unusual

NEW QUESTION/ANSWER

I don’t have any experience with J chain but is usually negative in RS-cells. MUM1 is typically positive but not specific.

NEW QUESTION/ANSWER

No

NEW QUESTION/ANSWER

Yes. J-chain and MEF2B have been reported to be useful as well. PMID: 28851661

NEW QUESTION/ANSWER

I don’t think it is particularly helpful, some cases of cHL may have rearranged IGH

NEW QUESTION/ANSWER

No

NEW QUESTION/ANSWER

I don’t find it that helpful

NEW QUESTION/ANSWER

There has been some data to suggest it is prognostic.

NEW QUESTION/ANSWER

It does not appear to commonly result in loss of CD30 expression in follow-up biopsy but I don’t believe this has been extensively studied.

NEW QUESTION/ANSWER

Yes, for T-cell lymphomas including cutaneous T-cell lymphomas it is reasonable to report the % positive tumor cells because some trials that resulted in the approval of brentuximab used specific cutoffs.